Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA052-1000  |   NCT07680764

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Resumen

  • Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 43
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
    1. Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
      1. Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.
        1. Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
          1. Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

            Criterios de exclusión

            Criterios de exclusión Icon
            • Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
              1. Participants must not have prior treatment with immuno-oncology therapies.
                1. Participants must not have untreated central nervous system (CNS) metastases.
                  Información Adicional *
                  • Other protocol-defined Inclusion/Exclusion criteria apply.

                    Opciones de tratamiento

                    Brazos del estudio

                    INTERVENCIÓN ASIGNADA

                    Brazos del estudio

                    Experimental: Arm A

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pumitamig, Imzokitug

                    Brazos del estudio

                    Experimental: Arm B

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pumitamig, Imzokitug

                    Brazos del estudio

                    Experimental: Arm C

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pumitamig, Imzokitug

                    Brazos del estudio

                    Experimental: Arm D

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pumitamig
                    Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                    Verifique su elegibilidad
                    Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                    Compatibilizar con un estudio
                    Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                    Seleccione una ubicación del centro del estudio
                    Seleccione una ubicación del centro del estudio que sea conveniente para usted
                    Registrarse
                    Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                    Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias